Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NASDAQ:LTRN OTCMKTS:LTUS NASDAQ:OBSV NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$26.74+10.2%$26.77$16.81▼$39.71$424.97M1.08271,891 shs1.59 million shsLTRNLantern Pharma$3.86+5.2%$3.14$1.11▼$5.74$49.25M2.32201,705 shs147,049 shsLTUSLotus Pharmaceuticals$0.00$0.00$0.00▼$0.01$8.20M-1.682,428 shsN/AOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shsN/AOVIDOvid Therapeutics$2.55+5.4%$2.55$0.30▼$3.11$475.93M0.163.68 million shs22.55 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%+9.41%-3.57%-3.47%+54.48%LTRNLantern Pharma0.00%+3.32%+10.29%+244.64%+24.12%LTUSLotus Pharmaceuticals0.00%-29.55%-13.89%-13.89%-56.34%OBSVObsEva0.00%0.00%0.00%0.00%-50.00%OVIDOvid Therapeutics0.00%+12.33%-3.41%+10.87%+710.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$26.74+10.2%$26.77$16.81▼$39.71$424.97M1.08271,891 shs1.59 million shsLTRNLantern Pharma$3.86+5.2%$3.14$1.11▼$5.74$49.25M2.32201,705 shs147,049 shsLTUSLotus Pharmaceuticals$0.00$0.00$0.00▼$0.01$8.20M-1.682,428 shsN/AOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shsN/AOVIDOvid Therapeutics$2.55+5.4%$2.55$0.30▼$3.11$475.93M0.163.68 million shs22.55 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%+9.41%-3.57%-3.47%+54.48%LTRNLantern Pharma0.00%+3.32%+10.29%+244.64%+24.12%LTUSLotus Pharmaceuticals0.00%-29.55%-13.89%-13.89%-56.34%OBSVObsEva0.00%0.00%0.00%0.00%-50.00%OVIDOvid Therapeutics0.00%+12.33%-3.41%+10.87%+710.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.57Moderate Buy$44.0064.55% UpsideLTRNLantern Pharma 1.00SellN/AN/ALTUSLotus Pharmaceuticals 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/AOVIDOvid Therapeutics 2.89Moderate Buy$5.13100.98% UpsideCurrent Analyst Ratings BreakdownLatest OBSV, LTRN, OVID, ASMB, and LTUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026ASMBAssembly Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$40.00 ➝ $45.005/28/2026ASMBAssembly Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.005/22/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026OVIDOvid Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/7/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026ASMBAssembly Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.004/21/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ASMBAssembly Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/9/2026OVIDOvid Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $4.004/6/2026ASMBAssembly Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $43.00(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$72.30M5.88N/AN/A$13.04 per share2.05LTRNLantern PharmaN/AN/AN/AN/A$0.58 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/AOVIDOvid Therapeutics$7.25M65.65N/AN/A$1.00 per share2.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$6.12M-$0.11N/AN/AN/A-8.98%-4.21%-3.14%8/5/2026 (Estimated)LTRNLantern Pharma-$17.12M-$1.45N/AN/AN/AN/A-198.34%-129.08%8/12/2026 (Estimated)LTUSLotus Pharmaceuticals-$30KN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/AOVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%8/12/2026 (Estimated)Latest OBSV, LTRN, OVID, ASMB, and LTUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026LTRNLantern Pharma-$0.36-$0.30+$0.06-$0.30N/AN/A5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/7/2026Q1 2026ASMBAssembly Biosciences-$0.65-$0.54+$0.11-$0.54$9.27 million$8.21 million3/30/2026Q4 2025LTRNLantern Pharma-$0.46-$0.36+$0.10-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A6.656.65LTRNLantern PharmaN/A1.871.87LTUSLotus PharmaceuticalsN/AN/AN/AOBSVObsEvaN/A0.610.61OVIDOvid Therapeutics0.0610.1710.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%LTRNLantern Pharma28.62%LTUSLotus PharmaceuticalsN/AOBSVObsEva17.52%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.10%LTRNLantern Pharma8.50%LTUSLotus PharmaceuticalsN/AOBSVObsEva14.40%OVIDOvid Therapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences10015.89 million15.08 millionOptionableLTRNLantern Pharma2012.76 million11.67 millionOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableOVIDOvid Therapeutics60186.64 million173.58 millionOptionableOBSV, LTRN, OVID, ASMB, and LTUS HeadlinesRecent News About These CompaniesOvid Therapeutics (NASDAQ:OVID) Upgraded at Wall Street ZenJune 27 at 1:37 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)June 9, 2026 | theglobeandmail.comOvid Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2026 | globenewswire.comOvid Therapeutics Expands Board, Appoints New Scientific DirectorJune 3, 2026 | tipranks.comOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of DirectorsJune 3, 2026 | globenewswire.comOvid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price TargetMay 26, 2026 | tipranks.comFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotechMay 15, 2026 | finance.yahoo.comWe're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash WiselyMay 14, 2026 | finance.yahoo.comOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comHere is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny StocksMay 9, 2026 | insidermonkey.com5 Best Fast Growing Penny Stocks to Buy Right NowMay 8, 2026 | insidermonkey.comOvid Therapeutics Inc.April 20, 2026 | edition.cnn.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN)April 17, 2026 | theglobeandmail.comOvid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - SlideshowApril 15, 2026 | seekingalpha.comOvid Therapeutics: Differentiated KCC2 ‘Master Switch’ Platform and Strong Cash Runway Underpin Buy RatingApril 15, 2026 | tipranks.comOvid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders TranscriptApril 14, 2026 | seekingalpha.comOvid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy RatingApril 9, 2026 | tipranks.comOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14April 8, 2026 | globenewswire.comOvid Therapeutics (OVID) price target increased by 14.29% to 4.87March 27, 2026 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Ovid Therapeutics (OVID)March 20, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Oracle’s Sell-Off Looks More Like a Mispricing Than a WarningBy Thomas Hughes | June 23, 20263 Inflation-Fighting Stocks Built for Higher Oil PricesBy Thomas Hughes | June 21, 2026Credo Technologies Accelerates AI—Its Stock Price Will FollowBy Thomas Hughes | June 18, 2026OBSV, LTRN, OVID, ASMB, and LTUS Company DescriptionsAssembly Biosciences NASDAQ:ASMB$26.74 +2.48 (+10.22%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$26.15 -0.59 (-2.20%) As of 06/26/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Lantern Pharma NASDAQ:LTRN$3.86 +0.19 (+5.18%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$3.86 0.00 (-0.13%) As of 06/26/2026 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0031 0.00 (0.00%) As of 06/26/2026Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Ovid Therapeutics NASDAQ:OVID$2.55 +0.13 (+5.37%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$2.56 +0.01 (+0.55%) As of 06/26/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
